Author:
AlKindi Salam,Dennison David,Pathare Anil
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference8 articles.
1. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 23:379–383
2. Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J (2004) Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89(5):520–527
3. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E, Gisslinger H (2004) Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 101(10):2239–2246
4. Data on file (Prod Info Agrylin(TM), (1999))
5. Wright CA, Tefferi AA (2001) A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 66:152–159
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献